Vaderis Therapeutics closed a $152 million Series B to fund operations through regulatory submissions and potential U.S. approval of engasertib.
- Amount
- $152M
- Stage
- Series B
- Announced
- 11 August 2026
- Leads
- Life Sciences at Goldman Sachs Alternatives, TCGX
- Other investors
- Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi, Droia
- Use of funds
- Fund planned operations through regulatory submissions and potential U.S. regulatory approval.
- Checked
- Announced by the company